2 recruiting, 1 completed, 1 unknown. 2 Phase 2, 1 Early Phase 1, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Unknown 1 |
| Early Phase 1 | 1 | Recruiting 1 |
| Phase 1 | 1 | Unknown 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow B ALL: new trials by email Literature Review of B ALL trials Research Report on B ALL
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CD19 CAR-T vs DLI for Post-HSCT MRD in Ph- ALL: A RCT CAR-T, DLI - B ALL, Allogenetic Hematopoietic Stem Cell Transplantation | Phase 3 | Recruiting | Peking University People's Hospital | 70 | 2025-11-30 | 2026-02-27 |
| Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma 131-I Apamistamab, CAR T-cell - B-ALL, DLBCL | Early Phase 1 | Recruiting | Memorial Sloan Kettering Cancer Center | 12 | 2021-02-02 | 2026-02-17 |
| Dual Target CAR-T Cells in B-cell Acute Lymphoblastic Leukemia Dual target CAR-T cell therapy - Dual-target CAR-T Cells, B ALL | Phase 1 / Phase 2 | Unknown | Shenzhen University General Hospital | 20 | 2020-10-20 | 2021-01-26 |
| Multi-centric Study Epratuzumab - B ALL, CD22+ Expression | Phase 2 | Completed | Nantes University Hospital | 57 | 2010-11-01 | 2026-09-14 |
Burkitt Lymphoma (1) · Lymphoma, Large B-Cell, Diffuse (1) · Neoplasm, Residual (1) · Pyloric Stenosis, Hypertrophic (1) · Recurrence (1)
Neoplasms (3) · Hemic and Lymphatic Diseases (2) · Immune System Diseases (2) · Immunoproliferative Disorders (2) · Lymphatic Diseases (2) · Lymphoma (2) · Lymphoma, B-Cell (2) · Lymphoma, Non-Hodgkin (2) · Lymphoproliferative Disorders (2) · Neoplasms by Histologic Type (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · DNA Virus Infections (1) · Digestive System Diseases (1) · Disease Attributes (1)
Immunotherapy, Adoptive (1) · epratuzumab (1)
Memorial Sloan Kettering Cancer Center (1) · Nantes University Hospital (1) · Peking University People's Hospital (1) · Shenzhen University General Hospital (1)
China (2) · France (1) · United States (1)
Li Yu, Dr (1) · Mark B Geyer, MD (1)